Month: July 2014

Oncology Therapeutics Making Big in Coming Years

Posted on Updated on

The industry’s 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche’s Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table. With combined sales of around $21 billion, these three drugs alone accounted for approximately 56 percent of the combined value of the 10 biggest-selling products.

Top 10 Oncology Drug Sales

Drug Name Company
Rituxan/MabThera Roche, Pharmstandard
Avastin Roche
Herceptin Roche
Gleevec  Novartis
Alimta Eli Lilly
Velcade Johnson & Johnson, Takeda,Pharmstandard
Erbitux Merck KGaA, Bristol-Myers Squibb
Lupron, Eligard AbbVie and Takeda; Sanofi   and Astellas Pharma
Zytiga Johnson & Johnson
Revlimid

Celgene, Pharmstandard

Rituxan is developed by Roche’s Genentech which is the first monoclonal antibody treatment for cancer. And even after 15 years on the market, it continues to see its sales grow, up 6% for Roche in 2013. The drug is also approved to treat a number of cancers, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia (CLL), it also works against rheumatoid arthritis and generates about $1.2 billion a year in that category.

By comparing the sales of all the drugs the Roche company becomes the king of all the Pharmaceutical Companies involved in making oncology drugs.

Let’s have a look over the ranking on the basis of oncology sales 2013.

Top 10 Best Selling Oncology Drug Companies

Roche has topped the ranking by its top selling drugs, followed by Amgen, Novartis, Celgene, Johnson and Johnson, Lily, Astrazeneca, Merck, BMS and Takeda.

Advertisements

Successful Launch of Mechanism of Action Based Pipeline Reports by DelveInsight

Posted on Updated on

Get the idea what Other Companies are doing with the Targets you are Interested In and what their progress and strategize to get the best out of it with our MOA Pipeline Reports.

After a successful launch of Drug and Indication Reports under Pharm Delve Series, DelveInsight has come up with a Pipeline Reports under brand name Pharm Insights covering 700+ Mechanism of Action reports.

Mechanism of Action Based Reports is one of a kind report which will provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). This report provides information on the therapeutic development based on the certain MOA dealing with the target, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the company’s information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

“In this highly competitive world, everybody wants to understand the pace of their competitors. Mechanism of Action based reports is the key for them” said Ms Mridhu Verma, Analyst at DelveInsight.

These reports can be available through leading resellers such as Report Linker’s, Report Buyer’s and Report stack or you can directly contact at info@delveinsight.com.

Pharm Insights-Coverpage

Compare the Global Sales of Blockbuster Drugs Losing Patent this Year (2014)

Posted on

Compare the global sales of 2013 and 2012 of the top ten blockbuster drugs which is losing patent this year. Teva Pharmaceutical’s Copaxone is the most affected drugs in terms of sales as the sales of 2013 has increased to 4.328 billions bearing the highest loss. Least affected Drug is AbbVie’s Trilipix which has faced the decrease in sales from 1.098 billions to 303 millions.

Blockbuster Drugs Global Sales 2012-13
Blockbuster Drugs Global Sales 2012-13

 

Table: Global Sales of Blockbuster Drugs for 2012 and 2013

Brand Name Global Sales 2012 USD (b) Global Sales 2013

USD (b)

Copaxone 3.996 4.328
Nexium 3.994 3.872
Micardis/Micardis HCT 2.217 0.97
Sandostatin LAR 1.512 1.589
Exforge/Exforge HCT 1.352 1.456
Nasonex 1.268 1.335
Trilipix 1.098 0.303
Evista 1.01 1.05
Renagel/Renvela 0.861 0.75
Restasis 0.792 0.94

Celecoxib first Generic Approval to Teva and Mylan from FDA

Posted on

On May 30, 2014, the U.S. Food and Drug Administration approved the first generic versions of Celebrex (celecoxib) capsules. Teva Pharmaceutical Industries received approval to market celecoxib capsules in 50 milligram, 100 mg, 200 mg, and 400 mg strengths, and has 180-day exclusivity on the 100 mg, 200 mg, and 400 mg strength products. Mylan Pharmaceuticals, Inc. received approval to market 50 mg celecoxib capsules.

Celebrex is a Pfizer’s blockbuster anti-inflammatory drug. Global sales of Celebrex exceeded USD2.1 billion, in the first nine months of 2013 which was a 13 percent increase on the same period the previous year.

Celebrex Global Sales till 2013
Celebrex Global Sales till 2013

 Patent protection from US16059493A originally expiring in November 2013 in the US, paediatric extensions have extended the expiry of the molecule and composition patents, US 5,466,823 (‘823) and US 5,563,165 (‘165), a further six months, until May 2014. This was the primary hurdle for the companies wishing to develop generic equivalents.

 Celecoxib is a selective COX-2 sulphonamide non-steroidal anti-inflammatory drug (NSAID), marketed by Pfizer, Pharmacia and G.D. Searle (both subsidiaries of Pfizer) under brand name Celebrex, Celebra for arthritis and Onsenal for polyps. It is indicated for use in the treatment of osteoarthritis, rheumatoid arthritis in patients 2 years or older, ankylosing spondylitis, acute pain and primary dysmenorrheal.

EMA Biosimilars Approvals

Posted on Updated on

In the European Union (EU), a legal framework for approving biosimilars was established in 2003. This framework means that biosimilars can only be approved centrally via the European Medicines Agency (EMA) and not nationally.

On 27 June 2014, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) had recommended granting of marketing authorization for a biosimilar insulin glargine product (LY2963016).

Eli Lilly and its partner Boehringer Ingelheim has produced the biosimilar insulin glargine, which will be called as Abasria (LY2963016). The drug is a biosimilar of French drugmaker Sanofi’s diabetes drug Lantus (insulin glargine).

To date, EMA has approved 21 biosimilars within the product classes of human growth hormone, granulocyte colony-stimulating factor, erythropoietin, insulin and TNF-inhibitor, for use in the EU.

Two biosimilar approvals have been withdrawn; one for filgrastim in April 2011 and one for somatropin in May 2012, leaving a total of 19 biosimilars approved for use in Europe.

 

EMA  BIOSIMILAR APPROVALS

DelveInsight- Business Consultant and Knowledge Partner

Posted on Updated on

We DELVEINSIGHT are Business Consultant and Knowledge Partner and have extensive experience across the value chain of pharmaceutical industry. Our company can provide valuable insight across all Pharmaceutical industries which include Drug Manufacturing to API Manufacturers to Drug Research Companies. We can help you in building clients for your business and can help you in expanding your business while providing you the marketing strategies and therefore enabling you to grow revenue. Our team of experts can analyze your current business practices and streamline your processes to increase your return on investment.

We have our proprietary Pharm Delve Platform for publishing multiple reports specific to Indication, Drug/Drug Classes covering the US, Europe, India, China and all emerging markets.

Currently we have 900+ Reports in the market for Indications and Drugs which can be further customized based on your needs.

Please contact us if you have any specific requirements at info@delveinsight.com

You can also visit our website for more information w: www.delveinsight.com